Concepedia

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

Norihiro Nishimoto, Koichi Amano, Yasuhiko Hirabayashi, Takahiko Horiuchi, Tomonori Ishii, Mitsuhiro Iwahashi, Masahiro Iwamoto, Hitoshi Kohsaka, Masakazu Kondo, Tsukasa Matsubara,

Modern Rheumatology · 2013 · 119 citations · 28 references

DOI

Abstract

TCZ monotherapy may induce biologics-free remission or LDA without concomitant use of synthetic DMARDs. Serum levels of IL-6 and MMP-3 are useful markers for identifying patients who could discontinue TCZ without acute disease flare.

References

28

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

Frank C. Arnett, Steven M. Edworthy, D. Blöch et al. · Arthritis & Rheumatism · 1988 · 19.8K citations

Revised Criteria for the Classification of Rheumatoid Arthritis

Frank C. Arnett · Orthopaedic Nursing · 1990 · 7.7K citations

, , +10

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

Catriona Grigor, Hilary A. Capell, A. Stirling et al. · The Lancet · 2004 · 1.4K citations

, , +8

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Josef S Smolen, André Beaulieu, Andrea Rubbert‐Roth et al. · The Lancet · 2008 · 1.4K citations

, , +10

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

Paul Emery, Edward Keystone, Hans‐Peter Tony et al. · Annals of the Rheumatic Diseases · 2008 · 1.1K citations · Full text